here - DDNews

integrated
coverage of the
pharma pipeline
from the bench to
the boardroom
■■
■■
■■
■■
■■
■■
DISCOVERY
RESEARCH &
DEVELOPMENT
PRECLINICAL
CLINICAL TRIALS
DIAGNOSTICS
BUSINESS &
GOVERNMENT
POLICY
2014 MEDIA KIT
DDNews website
From publishing our first
edition in January 2005 to
celebrating our tenth year
in 2014, DDNews continues
its dedication to delivering
the news of technology
and business in the
pharmaceutical, life science
and biotechnology industries.
For DDNews, a story lead or news announcement is just the
starting point for our editors. From here, they hit the phones and
conduct interviews with the principals involved in a story—and
often those not directly involved— giving an outside perspective.
They dig to get the “story behind the story,” always with a keen
eye toward how the story affects the industry.
Knowing that people get their information from more than one
source, we offer 15 fully integrated “touch points” to deliver our
industry news to our readers.
Our monthly print edition, which has a circulation base of
32,500 drug-discovery research professionals throughout North
America, delivers news that is specific to the pharma/biotech/life
science industries. Our digital edition reaches an additional
5,000 subscribers around the globe – for a total of 37,600.
And of course there is the DDNews website, a fully integrated,
online news portal housing all of our in-depth content, industry
resources, product literature, white papers and archived print
issues. With EditConnect and AdvConnect features, we provide
our readers with links to additional editorial and product resources
that don’t always make it to the print edition. DDNews’ web usage
last year generated more than 8.2 million downloaded pages.
The readers of DDNews’ various vehicles include senior
management; lab managers; group leaders, VP/Directors of R&D,
principal investigators and scientists in pharma/biopharma/
biotech companies; research professionals in academia involved
in pharma R&D; CROs; government agencies; and clinical trials
consultants/companies. We will continue to invest in these
important news vehicles as our audience continues to grow and
the industry continues to evolve.
Global inTeGraTed marKeTinG
monThly norTh america
prinT ediTion
webinars
Focus Groups
cusTom hTml’s
bi-weeKly
newsleTTer
■■
■■
ddnews cancer research news
DDNews Cancer Research News – launched in 2011 – houses
all of our reporting on the latest oncology research news, trends
and resources. This standalone website showcases all of our
cancer-related coverage, features some of the industry’s oncology
leaders and serves as a bridge between the reader and the cancer
community. In addition, a special RSS feed puts readers just one
click away from our up-to-the-minute cancer-related headlines.
DDNews online
DDNews Online is our twice-monthly; opt-in, subscription-based
e-newsletter reaching more than 82,000 subscribers worldwide.
This e-newsletter covers breaking business stories as well as
recent significant research findings, while giving subscribers a
gateway to major industry conferences and events.
e-conFerences
inTernaTional
diGiTal ediTion
Top-5 Stories
E-Table of
Contents
Fully
inTeGraTed
websiTe
■■
■■
■■
■■
Whitepapers/
Application
Notes
Research
Portals
Oncology
News Website
Online
Video
Circulation
Demographic
Analysis
Job TiTle
ToTal
producTs used
ToTal
percenT
oF ToTal
ADME/TOX
11,242
29.9%
Assay Development
17,182
45.7%
Bioinformatics
16,731
44.5%
Cellular Analysis
17,859
47.5%
Cell/Tissue Culture
17,069
45.4%
Chromatography
24,439
65.0%
Crystallography
16,581
44.1%
DNA Sequencing
17,558
46.7%
Electrophoresis
15,114
40.2%
Epigenetics
21,732
57.8%
percenT
oF ToTal
Flow Cytometry
16,092
42.8%
Fluorescence
17,596
46.8%
Academic Department Head/Chair
500
1.3%
Gene Expression
16,806
44.7%
Business Development/Finance/Legal
1,728
4.6%
Genotyping
17,295
46.0%
CEO/President/Executive
3,042
8.1%
HPLC
18,837
50.1%
Consultant
1,456
3.9%
HTS
17,220
45.8%
Group or Section Leader
3,241
8.6%
Image Analysis
16,769
44.6%
Lab Directory/Lab Mgr/Dept Mgr
4,254
11.3%
Immunology
14,250
37.9%
Principle Investigator
2,249
6.0%
Label Free Detection
14,889
39.6%
Production/Process Engineer
439
1.2%
Mass Spectroscopy
23,724
63.1%
Professor/Instructor
1,700
4.5%
Micro Arrays
15,753
41.9%
Purchasing Agent/Manager
224
0.6%
Microplate Analysis
17,182
45.7%
Research Assistant/Grad Student/Post Doc
1,757
4.7%
Nucleic Acid/ Oligos
16,393
43.6%
Research Diretory/VP of Reserrch
3,469
9.2%
PCR
17,709
47.1%
Research Scientist
13,063
34.8%
qPCR
17,032
45.3%
Other
467
1.2%
Protein Expression
16,129
42.9%
Proteomics
16,656
44.3%
Purification
17,220
45.8%
RNAi/saran
16,881
44.9%
Stem Cell
21,807
58.0%
Translational Research
17,032
45.3%
indusTry
ToTal
percenT
oF ToTal
Field & discipline
ToTal
percenT
oF ToTal
Bioanalytical Chemistry
14,287
38.0%
Biochemistry
15,415
41.0%
Cell Biology
13,648
36.3%
Clinical Diagnostics
13,535
36.0%
Development/Manufacturing
12,595
33.5%
Genomics/Genetics
12,144
32.3%
Pharmaceutical
13,673
36.4%
Medicinal/Organic Chemistry
14,062
37.4%
Biopharmaceutical
4,657
12.4%
Microbiology
12,821
34.1%
Biotech
9,368
24.9%
Molecular Biology
11,166
29.7%
Consulting firms
963
2.6%
Neuroscience
15,641
41.6%
Contact Research Manufacturing
658
1.8%
Oncology
11,354
30.2%
Government
1,157
3.1%
Pharmacology
10,377
27.6%
Clinical Research/Hospital/Medical Center
2,031
5.4%
Proteomics/Protein Chemistry
5,827
15.5%
Private Research/Independent
741
2.0%
Toxicology
5,715
15.2%
University/College
4,137
11.0%
Other
4,511
12.0%
Other
204
0.5%
Circulation
Geographic
Analysis
cenTral/souTh america
ToTal
percenT
oF ToTal
Argentina
14
0%
Brazil
58
.2%
Chile
22
.1%
Colombia
8
0%
Costa Rica
3
0%
Ecuador
2
0%
Nicaragua
2
0%
Panama
2
0%
Peru
2
0%
Other
17
0%
129
.3%
asia/paciFic
ToTal
percenT
oF ToTal
norTh america
ToTal
percenT
oF ToTal
Canada
497
1.3%
United States
32,599
86.7%
Mexico
172
.5%
Afghanistan
3
0%
33,268
88.5%
Australia
119
.3%
China
75
.2%
ToTal
percenT
oF ToTal
Hong Kong
52
.1%
India
346
.9%
.1%
Indonesia
20
.1%
.3%
Malaysia
80
.2%
0%
New Zealand
31
.1%
.1%
Philippines
20
.1%
133
.4%
europe
Austria
Belgium
Czech Republic
Denmark
39
115
17
53
Finland
67
.2%
Republic Of Korea
France
322
.9%
Singapore
89
.2%
Germany
275
.7%
Taiwan
44
.1%
Greece
73
.2%
Thailand
34
.1%
Hungary
45
.1%
Other
14
0%
Ireland
56
.1%
1,063
2.8%
Italy
188
.5%
Netherlands
109
.3%
aFrica/middle easT
ToTal
Norway
14
0%
percenT
oF ToTal
Poland
25
.1%
Egypt
75
.2%
Portugal
34
.1%
Iran
6
0%
Russian Federation
10
0%
Iraq
3
0%
Spain
167
.4%
Israel
39
.1%
Sweden
97
.3%
Jordan
13
0%
Switzerland
133
.4%
Lebanon
2
0%
Turkey
21
.1%
Saudi Arabia
17
0%
United Kingdom
956
2.5%
South Africa
103
.3%
Other
36
.1%
Other
19
.1%
2,852
7.6%
277
.7%
37,589
100%
* All USA copies are print edition, all others delivered digitally.
ToTal
Reach at Top
Biotech Companies
rank*
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
company
Roche
Amgen
Gilead Sciences
Novo Nordisk
Biogen Idec
Celgene
Shire PLC
UCB
CSL
Grifols SA
Actelion
Ipsen
Vertex Pharmaceuticals
Regeneron Pharmaceuticals
Elan
Alexion Pharmaceuticals
Cubist Pharmaceuticals
United Therapeutics
LFB Group
Alkermes
The Medicines. Co
Questcor Pharmaceuticals
BioMarin Pharmaceutical
Biocon Limited
Onyx Pharmaceuticals
ViroPharma
PDL BioPharma
Dendreon
Acorda Therapeutics
Swedish Orphan Biovitrum
Emergent BioSolutions
Spectrum Pharmaceuticals
Seattle Genetics
Galapagos NV
Medivation
Bavarian Nordic AS
SciClone Pharmaceuticals
NPS Pharmaceuticals
Cangene Corp
3SBio
Enzo Biochem
Isis Pharmaceuticals
Optimer
Zeltia SA
MorphoSys AG
AMAG Pharmaceuticals
Array Biopharma
Genmab AS
Nektar Therapeutics
Anika Therapeutics
print
subscribers
813
930
576
132
343
283
61
33
19
8
26
4
267
125
186
214
134
78
14
59
24
15
31
16
102
77
44
23
15
16
86
23
14
3
15
2
22
17
7
5
44
65
11
3
12
74
19
3
41
23
*Rank based on worldwide sales (Valid September 1, 2013)
e-news
subscribers
1,840
1,774
765
239
1,064
520
219
187
149
19
96
9
486
219
243
238
254
115
31
184
43
64
53
105
83
158
77
37
35
28
104
51
49
9
85
8
46
49
21
11
121
96
30
8
23
121
65
7
80
42
Global
hQ base
Switzerland
USA
USA
Denmark
USA
USA
UK
Belgium
Australia
Spain
Switzerland
France
USA
USA
Ireland
USA
USA
USA
France
USA
USA
USA
USA
India
USA
USA
USA
USA
USA
Sweden
USA
USA
USA
Belgium
USA
Denmark
USA
USA
Canada
China
USA
USA
USA
Spain
Germany
USA
USA
Denmark
USA
USA
Reach at Top
Pharmaceutical
Companies
Rank* company
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Johnson & Johnson
Pfizer
Novartis
Sanofi SA
Merck & Co.
GlaxoSmithKline
Abbott Laboratories
Roche
Bayer
AstraZeneca
Eli Lilly and Co.
Teva Pharmaceutical Industries
Boehringer Ingelheim
Bristol-Myers Squibb
Amgen
Takeda Pharmaceutical Co.
Merck KGaA
Baxter International
Astellas Pharma
Daiichi Sankyo
Gilead Sciences
Novo Nordisk
Otsuka Holdings
Mylan Laboratories
Eisai
Actavis
Allergan
Biogen Idec
Celgene
Servier
Shire PLC
Forest Laboratories
UCB SA
CSL Ltd
Manarini
Mitsubishi Tanabe Pharma
Hospira Inc
Kyowa Hakko Kogyo
Valeant
Dainippon Pharma
Fresenius
Endo Pharmaceuticals
Shionogi & Co.
Purdue
Lundbeck
Warner Chicott Plc
Grifols
Stada AG
Galderma
Ranbaxy Laboratories
print
e-news
subscribers subscribers
1,326
2,165
1,696
2,256
856
1,652
1,286
3,378
1,156
2,145
1,088
2,264
869
1,965
813
1,840
359
1,054
1,531
2,325
873
1,756
267
793
746
1,275
1,064
2,260
930
1,774
55
313
44
176
93
307
31
47
11
50
576
765
132
239
12
32
46
108
53
210
62
262
98
299
343
1,064
283
520
7
11
61
219
59
216
33
187
19
149
10
26
4
19
27
51
8
14
26
57
3
17
19
28
68
231
4
9
27
97
67
129
15
26
8
19
6
23
15
32
17
48
*Rank based on worldwide sales (Valid September 1, 2013)
Global
hQ base
USA
USA
Switzerland
France
USA
UK
USA
Switzerland
Germany
UK
USA
Israel
Germany
USA
USA
Japan
Germany
USA
Japan
Japan
USA
Denmark
Japan
USA
Japan
USA
USA
USA
USA
France
UK
USA
Belgium
Australia
Italy
Japan
USA
Japan
Canada
Japan
Germany
USA
Japan
USA
Denmark
USA
Spain
Germany
Switzerland
India
EDiToRiAl P l a n n e r
January
Issue Focus/
Special Topics:
■■
Diabetes/
Metabolic Disease
Bonus Distribution:
PepTalk
■■ Molecular Medicine
Tri-Conference
■■
February
Issue Focus/
Special Topics:
Biologics
Pittcon Show Feature
■■ Readex Study
■■
AACR Show Feature
Bonus Distribution:
■■
Point-Of-Care
Diagnostics
Bonus Distribution:
Experimental Bio
■■ PEGS
■■ BioMarker World
Congress
may
June
Issue Focus/
Special Topics:
Issue Focus/
Special Topics:
■■
Cancer
Bonus Distribution:
ISSCR
■■ ASM
■■ TIDES
■■ BIO
■■ World Pharma Congress
■■
Note: The SLAS2015 Show Feature issue will be in the January 2015 issue.
Issue Focus/
Special Topics:
■■
■■
Nanomedicine
Readex Study
Bonus Distribution:
ELRIG
Pharma Outsourcing
■■ MipTec
■■
april
Issue Focus/
Special Topics:
auGusT
■■
ToxExpo
■■ X-GeCongress
■■ BioPharm Asia
■■
ISSCR Show Feature
Readex Study
Next GeDX Summit
■■
■■
■■
■■
Bonus Distribution:
■■
■■
Cell Biology
■■
■■
Bonus Distribution:
AACR
Bio Therapeutics
■■ World OrphaDrug
Congress
■■ Bio-IT World
Issue Focus/
Special Topics:
■■
march
Issue Focus/
Special Topics:
July
sepTember
Issue Focus/
Special Topics:
■■
ASHG Show Feature
Bonus Distribution:
■■
■■
ASHG
NIH Research Festival
ocTober
Issue Focus/
Special Topics:
■■
Neuroscience
GDDIS
■■ Discovery on Target
■■
■■
november
Issue Focus/
Special Topics:
Disease Modeling
Cell Biology
Show Feature
■■ Readex Study
■■
december
Issue Focus/
Special Topics:
■■
■■
Bonus Distribution:
■■
Cell Biology
Neuroscience
Bonus Distribution:
PepTalk 2015
Show Feature
Bonus Distribution:
■■
■■
PepTalk
Antibody Engineering
Advertising Rates
rate card #10
Tabloid paGe
1-x
4-x
6-x
8-x
12-x
18-x
24-x
Tab spread
$16,220
$15,130
$14,290
$13,620
$13,060
$12,660
$12,230
1/2 Tab spread
$12,120
$11,330
$10,760
$10,280
$9,890
$9,610
$9,300
Tab page
$9,100
$8,720
$8,230
$7,990
$7,670
$7,440
$7,230
1/2 Tab page
$7,080
$6,680
$6,200
$6,070
$5,880
$5,710
$5,550
1/3 Tab page
$5,490
$5,240
$4,980
$4,820
$4,620
$4,520
$4,450
sTandard paGe
1-x
4-x
6-x
8-x
12-x
18-x
24-x
standard spread
$13,790
$12,940
$12,320
$11,760
$11,330
$11,040
$10,690
standard page
$7,670
$7,050
$6,850
$6,580
$6,280
$6,130
$6,000
2/3 standard page
$6,500
$6,120
$5,830
$5,600
$5,440
$5,280
$5,150
1/2 standard page
$5,550
$4,920
$5,030
$4,830
$4,700
$4,560
$4,470
1/3 standard page
$3,490
$3,280
$3,130
$3,000
$2,890
$2,810
$2,730
1/4 standard page
$3,020
$2,850
$2,710
$2,610
$2,530
$2,470
$2,390
1/6 standard page
$2,550
$2,420
$2,310
$2,240
$2,150
$2,120
$2,070
cover banner
$3,750
$3,750
$3,750
$3,750
$3,750
––––––
––––––
TERMS AND CONDITIONS:
Cancellation of any contract requires 60 days written notice.
special posiTions
earned rate plus
cover 2
15%
Standard 15% agency discount is given to recognized agency on
space charges only if paid within 30 days of invoice date.
cover 3
10%
All page rates are gross and include 4-color.
cover 4
20%
consecutive fraction ads
15%
all other guaranteed positions
10%
AGENCY COMMISSION:
inserTs & impacT pieces
net per
4 page insert – standard supplied
$14,490 net
2 page insert – standard supplied
$7,940 net
2-color belly band
$23,160 net
4-color belly band
$23,720 net
Full page cover tip on
$12,660 net
Gatefold
$29,190 net
Digital non-USA edition
net
per Tab
paGe
Tab
spread
issue
sponsorship*
$1,690
$2,810
$5,620
* Issue sponsorship includes opening message with your logo,
one tab spread or two single tab ads.
e-newsletter
Our biweekly e-newsletter keeps
readers around the world informed
of late breaking news, updates,
analysis, upcoming industry events,
and commentary.
Distributed the second and
fourth Wednesday of each
month to 82,000 plus
qualified recipents.
Electronic
Advertising
opportunities
E-NEWS | FOR:
WEDNESDAY
COMMENTARY:
Facts don't matter
By Peter T. Kissinge ... until they do
r
more>
NEWS BRIEFS:
Amgen and Onyx
finally seal an
acquisition deal
Amgen will acquire
for a total purchase Onyx Pharmaceuticals for
$125
portfolio... <more> price of $10.4 billion, boosting per share in cash,
Amgen's oncology
AstraZeneca's
une
BENCH PRESS:
CURRENT ISSUE:
RESEARCH
& DEVELOPMENT:
monoclonal
Making
antibodies for
multiple
myeloma
Germany's MorphoS
ys, Celgene sign
pact to develop
novel therapeu
tic anti
body for patients
with blood cell
more>
cancer
adverTisinG raTes (neT)
EVENTS | VIEW
ad size
1x-5x
6x-11x
12x-17x
120 x 90
$1,930
$1,620
$1,330
CALENDAR
120 x 600
$3,210
$2,900
$2,540
468 x 60
$3,870
$3,500
$3,210
2
3
4
5
6
7
9
10
11
12
13
14
15
16
17
18
19
20
21
ISSUE | DOWNLOA
22
23
24
D PDF
25
26
27
28
HOME
E
Search
Facebook
ABOUT US
S
ADVERTISING
G
RESOURCES
ES
S
Twitter
DAILY NEWS:
DAILY NEWS:
CONFERENCES
AND
EXHIBTIONS:
ddn MARKET
DON’T MISS
OUR
THREE-PART
SERIES ON
STEM CELL
RESEARCH
bioMérieux acquires
BioFire
Diagnostics
SPECIAL REPORTS
:
RESEARCH:
R:
SUBSCRIPTION:
SPONSORS:
Trio unites to
develop antiviral
drugs for dengue
virus
CIRM to award
$40 million to
stem
cell research
projects
PART 1: A place
for my cells
As collections
expand,
biorepositories
are bursting at
the
seams
Akorn acquires
Hi-Tech Pharmaca
for $640 million
l
$1,930
$2,540
CONTACT US
DDNEWS
Published by
Old River Publications
LLC
19035 Old Detroit
Road
Rocky River,
OH USA 44116
Ph: 440-331-660
0 | Fax: 440-331-756
3
COLLEAGUE
Banners must be in GIF or Animated GIF format only.
Banner size as noted above. Banners must be no larger than
20kb in size. No transparent GIF’s or SWF accepted.
| DDN PRINT
SUBSCRIPT
ION | UPDATE
EMAIL
ADDRESS
| Online Newsroom
| Unsubscribe
©2012 Old River
Publications LLC.
Web site designed
All Rights Reserved.
and managed
If you no longer
by Offenberg
er & White, Inc..
wish to receive
DDNEWS mailings,
please unsubscrib
e here.
PART 3: An eye
to stem cell
therapies
Despite the renewed
research
interests in stem
cells, therapeuti
push the market
cs
Sanford-Burnham
and Pfizer
collaborate to
tackle metabolic
disease
NEXT: Medicinal
November issue chemistry in our
TSRI scientists
devise
boost RNA treatment new way to
potency
Epigenetic effects:
From cancer
neurology
to
X Prize Foundatio
n nixes
genetics-oriented
prize
Shire and Santaris
extend rare
genetic disease
pact
INSIDE THIS
$2,290
$2,950
PART 2: Model
citizens
Stem cells’ promise
disease-in-a-dish of
opens doors
to
truly personaliz
ed medicine
Amgen and Onyx
finally seal an
acquisition deal
AstraZeneca’s
MedImmune
to
acquire Amplimmu
ne
Various ad sizes are
available on the home page
and news pages.
Ads are placed in rotation.
Maximum three deep rotation.
24x
$1,030
DDN Home |
Advertising |
Editorial Feedback
Baxter, Coherus
ink agreemen
t
worth up to $246
million
web advertising
reQuiremenTs:
FORWARD TO
Otsuka to acquire
Astex
Pharmaceuticals
for $886 million
INDUSTRY CALEDNA
E-NEWSLETTER
TOP STORY:
Almac, Queen’s
University
announce £13
million investmen
in cancer research
t
18x-23x
$1,150
CLINICAL TRIALS:
Tackling cancer
Tennessee
in
SCRI, AstraZen
eca
compounds, focus to develop oncology
on molecular
more>
profiling
CONTACT US
PRODUCT SPOTLIGHT:
EDIT CONNECT
THIS ISSUE:
OMICS & SYSTEM
S BIOLOGY:
Department
of Health launche U.K.'s
mapping effort
s DNA
Genomics England
at a better understa will lead effort aimed
nding of cancer,
and infectious
rare
diseases more>
TOOLS & TECHNO
LOGY: Leica
tems acquires
Kreatech DiagnosBiosysKreatech will
join Leica Biosyste tics
Advanced Staining
ms'
Business Unit
in Newcastle-upon-T
based
yne, U.K. more>
DIAGNOSTICS:
A 'sea change'
desert
in the
Arizona-based
TGen and Ventana
forces to meet
demand for diagnostjoin
cancer biomarke
ic
rs
regulators more> from pharma and
GLOBAL NEWS:
From Russia
drugs
with
Russian pharmac
eutical giant Pharm
standard extends
global reach with
acquisition more>
Bever
Month, Year
8
ION | VIEW LATEST
to acquire Amplimm
tackle metabol
ic
The compani
es will use novel
screening tools,
gy approaches
and
including systemsthe aim of discoveri technologies developed
at Sanford-Burnham biolong new therapeu
resistance in
obesity and diabetes tic strategies for reducing , with
insulin
... <more>
1
| VOL. 9 | NO.
MedImmune
MedImmune
will acquire 100
percent of Amplimm
initial consider
ation of $225
million and deferred une's shares for an
$275 million...
<more>
consideration
of up to
Sanford-Burnha
m and Pfizer
disease
collaborate to
TSRI scientist
s devise new
way to boost
RNA treatmen
t potency
Researchers
from The Scripps
to dramatically
Research Institute
raise the potency
describe a novel
resulting in a
way
2,500-fold improvemof drug candidates targeting
RNA,
ent in potency..
. <more>
Epigenetic effects:
From cancer
to neurology
UC Davis research
ers discover how
lence" the gene
for two rare neurodeva chemotherapy agent can
"un-sielopmental disorders
... <more>
8
August 2013
FEATURED:
We have a lot
of data, in life
sciences and
so many other
aspects of life,
but DDNEWS
columnist Peter
Kissinger fears
little in the way
there's too
of facts
choose and sometim as people pick and
es spin data to
result they want
get the
instead of the
result that is
accurate. And
as he notes, "I
am grumpy
because I now
understand why
Patrick Moyniha
Sen. Daniel
n said, 'You are
your opinion.
entitled to
But you are not
entitled to
your own facts.'"
Back To: Home
PRINT SUBSCRIPT
| August 2013
Jump to:
NEWS BRIEFS
BENCH PRESS
INDUSTRY CALENDA
R
CURRENT ISSUE
EDITORS FOCUS:
Ask, and science
may receive
ISSUE:
whitepapers
3 month posting
$1,600 net (per unit)
M&A madness
09-06-2013
Pharma and biotech
went on spending companies
spree this
summer...
by Amy Swinderm
an
Pharmas face
bribery charges
China
in
09-06-2013
GSK, Sanofi
and Lilly are suspected
of issuing bribes
to
by Kelsey Kaustinenboost sales...
Access to answers
09-06-2013
Databases are
designed
research for personaliz to facilitate
ed cancer
treatment ...
by Ilene Schneider
Form influence
s function
09-06-2013
Research indicates
that the shape
the genome significant
of
transcription regulationly influences
...
by Jeffrey Bouley
AstraZeneca
acquires
Pearl Therapeu
tics to
strengthen respirator
y
portfolio
August 2013
Acquisition could
be worth $1.15
billion, all told...
by Kelsey Kaustinen
Building a biologics
August 2013
PAGE UTILITIES
PAGE
SEND THIS PAGE
TO A COLLEAGUE
CONTACT US
boom
Fifth-generation
anticancer biologics
poised to enter
$120-billion market...
PRINT CURRENT
by Lloyd Dunlap
09-06-2013
For decades,
clinicians and
researchers have
been taking
leftover cells,
tissue,
organs from patients blood and
and using them
in the name of
advancing scientific
and medical research.
Tremendous
gains have been
realized from
these
leftovers, but
each milestone
has
been marked
by the unresolve
d
issue of informed
consent—because
sometimes, these
researche
rs are
not asking patients
if it’s OK to use
their leftovers.
..
by Amy Swinderman[ more ]
Out of Order:
09-06-2013
Inspired cynic
For a few days,
at least, this grumpy
old tech has regained
a degree of
excitement about
what
and what is possible. is out there
It’s a good
feeling, and one
that I wish for
everyone out
there... [ more
]
by Randall Wllis
Immuno-oncology:
The
importance of
combination
therapies
09-06-2013
Immuno-oncology
is gaining wide
acceptance as
a promising
therapeutic strategy
due to its
unique potential
to
clinical responses generate durable
Additionally, there in patients.
resulting proliferatiohas been a
immunotherapies n of cancer
in the clinical
pipeline... [ more
]
by Helen
Sabzevari, EMD
Serono
DDNEWS
Published by
Old River Publications
LLC
19035 Old Detroit
Road
Rocky River,
OH USA 44116
Ph: 440-331-6600
| Fax: 440-331-7563
Home | FAQs
| Search |
Submit News
Release | Site
Map | About
Us | Advertising
| Resources
© Copyright 2013
| Contact Us
| Terms & Conditions
Old River Publications
| Privacy Policy
LLC. All righs
reserved. | Web
site managed
and designed
by OffWhite.
adverTisinG raTes (neT)
ad size
one
month
3 months
per month
6 months
per month
12 months
per month
125 x 125
$2,490
$1,870
$1,620
$1,370
120 x 90
$1,870
$1,250
$990
$740
120 x 240
$2,740
$1,990
$1,750
$1,500
*468 x 60
$3,730
$2,620
$2,360
$2,110
**468 x 60
$2,940
$2,240
$2,010
$1,770
e-Top 5 stories
leaderboard (468 x 60)
Exclusive: $3,460 (net)
Shared: $3,150 (net)
Shared: $2,880 (net)
skyscraper (120 x 60)
reQuiremenTs:
Banners must be in GIF or animated
GIF format only. Banner size as noted
above. Banners must be no larger
than 20kb in size.
International
Society for Stem
Research (ISSC
Cell
R) Preview
Don't miss ddn's
preview of the
Research's (ISSCR)
International
Society for Stem
11th Annual Meeting
Cell
From stem to
No transparent GIF’s or SWF accepted.
Distributed by e-mail to 82,000 plus
qualified recipients.
shared: DDNews editor picks subjects,
shared sponsorship.
exclusive: client picks subject area,
sole sponsorship.
Oversight should
The ISSCR emphasnot be overlooked
izes the importan
cell products
ce of regulato
for clinical use,
ry oversight for
after a decision
the administration
stem
in Italy recently
of cells that have
authorizing
stem cells to
been describe
patients with
neurological disorder d as mesenchymal
s.
Industry Wednes
day Sympos
Thermo Fisher
ium
Scientific to present
Advancing Stem
"New Concept
Cell Research
s and Tools for
as part of the
and
Therape
utic Approach"
exhibition portion
symposium
of the annual
meeting.
ISSCR awards
At the ISSCR's
annual meeting
Award for Innovati
, the society will
present the McEwen
Young Investiga on, the ISSCR-University of
Pittsburgh Outstan
tor Award and
the ISSCR Public
ding
Service Award.
ISSCR figures
prominently
among winners
Breakthrough
of inaugural
Prize
Among the 11
distinguished
recipients announc
ISSCR notes
that
ed in Februar
y,
society and one it can boast two who have
a direct connect the
with a very timely,
ion to the
if indirect, connect
ion.
All coverage
E-Mail banners to: [email protected]
stern
SSCR meeting
keeps up with
the fast
pace of stem
cell research
by offering
increased technolo
gy element, expande
poster coverag
d
e and more. Find
what's new and
out
notable at the
ISSCR's
11th Annual Meeting
, which is being
in Boston this
held
year from June
12-15.
reQuiremenTs:
Banners must be in GIF or Animated GIF format only.
Banner size as noted above. Banners must be no larger
than 20kb in size. No transparent GIF’s or SWF accepted.
*Leaderboard **Footer banner.
May 2013
sponsored by
Life Technolo
gies
CONTACT US
DDNEWS
Published by
Old River Publications
LLC
19035 Old Detroit
Road
Rocky River,
OH USA 44116
Ph: 440-331-66
00 | Fax: 440-331-75
63
FORWARD TO
COLLEAGUE
| DDN PRINT
SUBSCRIP
TION
DDN Home |
Advertising |
Editorial Feedbac
k | Online Newsroo
m | Unsubsc
ribe
©2012 Old River
Publications LLC.
Web site designed
All Rights Reserved
and managed
.
If you no longer
by Offenberg
er & White, Inc..
wish to receive
DDNEWS mailings,
please unsubscri
be here.
E-Mail orders to: [email protected]
DDNews cancer website
Electronic
Advertising
opportunities
banners
one
month
3 months
per month
6 months
per month
12 months
per month
125 x 125
$1,870
$1,620
$1,370
$1,160
120 x 90
$1,250
$990
$740
$630
120 x 240
$1,990
$1,750
$1,500
$1,270
*468 x 60
$2,620
$2,360
$2,110
$1,790
**468 x 60
$2,240
$2,110
$1,770
$1,500
*Leaderboard
**Footer banner
SEARCH
Your gateway
to the latest oncolo
gy research new,
trends and resourc
es
ABOUT
HOME
IN THE SPOTLIGHT
3 month video posting
$2,000 (net)
DDNEWS Cancer
Research News
Monitoring cancer
US
S
EDITOR’S CHOICE
NEWS
OPINION
TOP 5
movement
DAILY NEWS:
Almac, Queen’s
University announce
investment in
£13 million
cancer research
FEATURES:
A robust innovation
Decision connected
to 'significant
milestone'
achieved in clinical
development
of new cancer
ALM201
drug
in oncology
alliance
SPONSORS:
Block and load
CRT, ICR and
Merck Serono
sign license deal
molecules to
on
block WNT signaling
pathway
(Photo credit:
Cancer Research
UK)
A computer model
of the movement
skin cells is being
of melanoma
used to study
how cancer cells
move in various
environments
in the body;
scientists hope
that by unlocking
the basis of that
movement, they
can block cancer
cells to
prevent their
spread and keep
them in place
GENEWIZ, BeiGene
partner for biomarkers
A collaboration
was recently
announced between
GENEWIZ Inc.
and BeiGene
to accelerate
biomarker discovery
cancer
Access to answers
SUBSCRIPTIO
(Photo credit:
Databases are
designed to facilitate
personalized
research for
cancer treatment
NS:
Impressing with
py
events on a single
slide
Clarient’s MultiOmyx
‘allows precision
become even
medicine to
more precise’
Amgen and Onyx
finally seal an
MedImmune
to acquire Amplimmune
MedImmune
will acquire 100
percent of
Amplimmune
’s shares for an
initial consideration
$225 million and
of
deferred consideration
$275 million
of up to
PAGE UTILITIES
PRINT CURRENT
PAGE
TO A COLLEAGUE
OPINION:
Ask, and science
may receive
acquisition deal
Amgen will acquire
Onyx Pharmaceuti
per share in cash,
cals for $125
for a total purchase
billion, boosting
price of $10.4
Amgen’s oncology
portfolio
AstraZeneca’s
UCSF)
Public-private
alliance will create
efficient partnership
opportunities
oncology drug
in
developmen
pathway discovery t and
immunothera
Bayer, Compugen
join forces on
antibody-based
cancer therapeutics
Up to 65 cellular
SEND THIS PAGE
LINKS
PRODUCT SPOTLIGHT:
Researchers
model the movement
cells to determine
of cancer
how to keep them
spreading
from
CONTACT US
VIDEO
Exclusive
09-06-2013
For decades,
clinicians and
researchers have
been taking
leftover cells,
tissue,
organs from patients blood and
and using
them in the name
of advancing
scientific and
medical research.
Tremendous
gains have been
realized from
these leftovers,
but
each milestone
has been
marked by the
unresolved issue
of informed consent—b
ecause
sometimes, these
researchers
are not asking
patients
to use their leftovers. if it’s OK
DDNEWS
Published by
Old River Publications
LLC
19035 Old Detroit
Road
Rocky River,
OH USA 44116
Ph: 440-331-6600
| Fax: 440-331-7563
Home | FAQs
| Search |
Submit News
© Copyright 2013
Release | Site
Map | About
Us | Advertising
| Resources
| Contact Us
| Terms & Conditions
LLC. All righs
| Privacy Policy
reserved. | Web
site managed
and designed
by OffWhite.
Old River Publications
e-products & services
A quarterly showcase of new products and services, available
with an optional imbedded three minute video/product
demonstration link. Distributed by e-mail to 82,000 plus
qualified recipients.
e-Table of contents
e-producTs & services (per uniT)
Banners must be in GIF or
Animated GIF format only.
Banner size as noted above.
Banners must be no larger than
20kb in size. No transparent
GIF’s or SWF accepted.
standard unit
unit with video
$1,060 (net)
$1,690 (net)
August 2013
New e-Products
leaderboard 468 x 60 $3,460 (net)
reQuiremenTs:
ddn January
JANUARY 2012
Curing from
hand to mouth
Gilead Scienc
es acquires Pharm
quickly advan
cing oral, non-in asset for $11 billion in hopes
terferon treatm
of more
ents for HCV
Growing steadi
ly downstream
Affymetrix to
acquire eBiosc
ience for $330
discovery-based
million in plan
efforts
to expand beyon
d
'The next big
thing is alread
y here'
Samsung further
s
joint venture with entrée into growing biosim
ilars market in
Biogen Idec
$300 million
Genes that fit
everyone
NIH division paves
path toward genom
ic medicine
EDITORIAL
Publisher's Note:
By Bruce Poorm Keeping our resolution
to report the
an, ddn Publis
news
her
From publish
ing our single
newsp
eighth year in
2012, ddn continu aper in January 2005 to celebr
disseminate the
es to produce
ating our
many vehicle
news.
s that
Out of Order
: Gift horses
By Randall C.
Willis
A quick Google
search for the
phrase
results in the
"outcomes-based
tens of thousa
medicine" yields
nds.
however, the
focus is on scienti When you look at a lot of
these results,
outcomes--wh
fic method and
ich is the point
not, ironically,
of medicine, isn't
on
it?
Examining recent
approaches
By Punit Dhillon
to
, OncoSec Medica treating solid tumors
According to
l
the Centers for
Disease Contro
cancer types
l and Prevention,
are in the solid
tumor catego
the top 10
higher. Thus,
ry; today, the
there
priority is likely
new, cost-efficient are clear unmet medical
even
needs, and the
and patient-friend
development
both the health
ly treatments
of
care community
remain a high
and patients.
priority for
August 2013
Automation Config
uration Made
Thermo Scien
Easy
tific iAutomate
Make your autom
ated workflow
iAutomate. See
a reality with
Thermo Scient
how this new
ific
online
plan and design
a laboratory autom tool can help you to easily
specific workfl
ation project to
ow requirement
suit your
s.
MORE INFOR
MATION:
Thermo Scien
tific iAutomate
|
SHOW PREVIE
W
Rebooted and
upgraded
The merged ALA
and
joint annual meetin SBS groups, now known
as SLAS, launch
g
Watch Video
first-ever
PLUS: The social
side of SLAS2
It's not all work
012
and
and social opport no play; don't miss our exclus
unities availab
ive guide to the
le to conference
networking
attendees in San
Diego.
GLOBA
Seahorse Introd
uces
Bioavailable Conju XF Palmitate-BSA FAO
Substrate, a
Seahorse Biosc gated Palmitate-BSA
ience
XF Palmitate-BS
A
conjugated fatty FAO Substrate is the only
bioava
acid available
today. This ready- ilable,
strate frees you
from the tediou
to-use subable conjugation
s, time-consum
ing, and variprocess, and
simpli
obtaining functio
nal data to charac fies the process for
type of cells.
terize the metab
XF Palmitate-BS
olic phenoA FAO Substrate
only from Seaho
is available
rse Bioscience
or Authorized
Distributor.
MORE INFOR
MATION:
Seahorse Biosc
ience | (978)
671-1600
| sales@seaho
rsebio.com
Mouse breast
cancer cell line
panel (ATCC®
ATCC
TCP-1005™)
ATCC now offers
the Breast Cance
Panel (ATCC
r Mouse Model
® TCP-1005™
Cell Line
). This panel
that stably overex
includes cell lines
press the MEK1
EGFR2/neu,
activated mutan
Myc,
t (MEKDD),
successfully used or Ha-Ras. These cell lines
have been
for studying metas to generate mouse models
of breast cance
tasis
and EGFR
r
oncogenes in
cell transformatio -MEK signaling pathways,
compounds.
n, and for testing
anti-cancer
MORE INFOR
MATION:
ATCC | (703)
365-2700 | sales@
atcc.org | tech@
atcc.org
The Missing Link:
Eppendorf Tube
Eppendorf
5.0mL
Use for anythi
ng from cell culture
making maste
r mixes and aliquo to routine liquid handling
like
make your protoc
ts -- the 5.0 mL
system can
ols much easier
accessories for
. With a compl
centrifugation,
incubation, mixing ete line of
of samples to
maximize your
, and storage
performance.
MORE INFOR
MATION:
Eppendorf |
800-645-3050
• More ergon
omic
• The same perfor than a 15 mL conical tube
mance as a 1.5
• The quality
mL tube
you have come
to expect from
Eppendorf
| info@eppen
dorf.com
Sealed in securi
ty.
F1-ClipTip Pipett Feel the difference with Therm
ing System
o Scientific
Thermo Scien
tific
MORE INFOR
MATIO
Contents
COVER
Distributed by e-mail to 82,000
plus qualified recipients.
and Services
2012 Table of
Reproducible
pipetti
Technology makes ng you can count on. Break
through ClipTip
With a light touch daily pipetting a totally new
experience.
your tips are
not loosen or
locked firmly
in place, and
fall off regard
will
less of applic
innovative three
ation pressure.
interlocking clip
The
securely on the
design ensure
s the tip is held
F1-ClipTip pipette
released. Worry
until,
and
only until, it is
-free pipetting
is finally here,
that clips.
with the only
tip
L NEWS
Good cop, bad
cop, market
share
Valeant shows
both its amiab
le and hostile
acquire Austra
sides with an
lia's iNova and
agreement to
a hostile bid to
Pharmaceutic
als
take over U.S.
company ISTA
A 'win, win, win'
for public-priva
AstraZeneca
te partners
launch
Council for discon es innovative partnership
with U.K.'s Medica
tinued drug compo
l Research
unds
The appeal of
zeal
Elan to join Cambr
idge in new resear
diseases
ch center aimed
at neurodegene
rative
The eyes have
it
Proximagen,
Altacor to collabo
rate on glauco
ma treatment
custom hTml e-mails
Get your product custom message out to the DDNews subscriber.
Cost is based on the number of print ads running in the print
edition of DDNews.
TOOLS & TECHN
OLOGY
Growth in India
AB SCIEX acquir
es
presence in India Labindia's mass spectrometry
divisio
raTes per mailinG
n to broaden
Corning Life
Sciences acquir
Corning to offer
es
customers a more Mediatech
bioprocess needs
complete solutio
n to their cell
culture and
Shopping for
companies during
Agilent Techno
the holidays
logies grows
life-science busine
in next-generat
ion sequencing
ss with strateg
ic acquisitions
and automated
pharma
analytical solutio
ns for
An unfolding
development
Expedeon and
Protein Discov
ery join forces
for protein resear
to provide advan
ch
ced products
up to 5,000
$2,500 (net)
5,000 to 6,500
$3,000 (net)
6,500 to 8,000
$3,500 (net)
8,000 to 10,000
$4,000 (net)
Mailings larger that 10,000 will be quoted
$500 net charge for split copy and/or headline per split.
DIAGNOSTICS
Roadmap to
theranostics
Researchers
award
biomolecule discov ed $3.2 million from NIH
Roadmap to pionee
ery technology
r advanced
Deal aggressivel
y targets oncolo
GSK and Abbott
gy Dx
expand collabo
diagnostic test
ration to develo
for several types
p additional compa
of cancer
nion
MDxHealth, Cellde
Companies begin x ink deal for brain cance
r test
Phase III study
for glioblastoma
multiforme test
Trauma on their
minds, treatm
Amarantus Bioscie
ent in their thoug
nces and Banya
hts
injury research
n
Biomarkers annou
collaboration
nce traumatic
brain
OMICS & SYSTE
MS BIOLOGY
Changing the
channel
UCB acquires
ion channel-targ
eting programs
from Lectus Therap
An alternative
eutics
to whole-geno
me sequencing
Roche Nimble
Gen,
disease and biome BGI unveil MHC region captur
e technology
dical research
for human
Going comm
ercial
Compugen, Discov
ligands for GPCR eRx form collaboration to
commercializ
drug targets
e novel peptid
e
Bruker goes
to Korea
Company wi
Production
Specifications
mechanical specs
■■
■■
■■
bleeds
width x height (inches)
■■
Tab Page
Half Tab–Horiz.
10-7/8 x 14-1/8 bleed
10-5/8 x 13-7/8 trim
10-7/8 x 7-3/16 bleed
10-5/8 x 6-15/16 trim
Half Tab–Vert.
5-1/2 x 14-1/8 bleed
5-1/4 x 13-7/8 trim
1/3 Tab–Horiz.
10-7/8 x 5-5/8 bleed
10-5/8 x 5-3/8 trim
1/3 Tab–Vert.
3-9/16 x 14-1/8 bleed
3-5/16 x 13-7/8 trim
Tab Spread
21-1/2 x 14-1/8 bleed
21-1/4 x 13-7/8 trim
Standard Page
Standard Spread
non-bleeds
Tab Spread
Tab Page
Half Tab–Horiz.
Half Tab–Vert.
1/3 Tab–Horiz.
1/3 Tab–Vert.
standard pages
Spread (non-bleed)
Page (non-bleed)
2/3 Page
1/2 Page–Island
1/2 Page–Horiz.
1/2 Page–Vert.
1/3 Page–Vert.
1/3 Page–Square
1/4 Page–Vert.
1/6 Page–Vert.
8-3/8 x 10-7/8 bleed
8-1/8 x 10-5/8 trim
16-1/2 x 10-7/8 bleed
16-1/4 x 10-5/8 trim
width x height (inches)
20-1/4 x 12-7/8
9-5/8 x 12-7/8
9-5/8 x 6-5/16
4-5/8 x 12-1/2
9-5/8 x 4-7/8
2-13/16 x 12-7/8
width x height (inches)
15 x 10
7 x 10
4-9/16 x 10
4-9/16 x 7-1/2
7 x 4-7/8
3-3/8 x 10
2-3/16 x 10
4-9/16 x 4-7/8
3-3/8 x 4-7/8
2-3/16 x 4-7/8
■■
■■
Acceptable digital file formats: PDF or composite TIFF or EPS
files with pictures/art and fonts embedded.
Bleed ads should have 1/8-inch bleed on all sides and
crop marks should be offset by 12 pts.
All pictures should be at least 300 dpi at printed size for
CMYK and grayscale; 600 dpi for line art.
Total ink density not to exceed 260%. 110 line screen.
All color is CMYK. PMS or spot colors are not accepted.
Please send color proofs at 100%. Without a proof, DDNews
cannot be held responsible for the optimum outcome of color.
SWOP Standards apply.
e-mail ad maTerials
To [email protected] include the advertiser’s name and
issue date in the subject line.
FTp ad maTerials
For instructions go to www.ddn-news.com/ftp
2014 production schedule
issue date
space closing
materials date
January 2014
December 2
December 6
February 2014
January 6
January 10
March 2014
February 3
February 7
April 2014
March 3
March 7
May 2014
April 7
April 11
June 2014
May 5
May 9
July 2014
June 2
June 6
August 2014
July 7
July 11
September 2014
August 4
August 8
October 2014
September 2
September 5
November 2014
October 6
October 10
December 2014
November 3
November 7
advertising sales representatives
norTheasT
old river publicaTions
19035 Old Detroit Road, Suite 203
Rocky River, OH 44116
Tel: 440-331-6600 Fax: 440-331-7563
midwesT, midaTlanTic, souTheasT
sTeve loerch
Tel: 847-498-4520 Fax: 847-498-5911
[email protected]
wesT and souThwesT includinG:
AR, AZ, CA, CO, ID, LA, MT, NM, NV, OK,
OR, UT, TX WA, WY, Western Canada
KayTe miller
Tel: 510-759-7529
[email protected]
europe, aFrica, asia
sTephanie painTer
Tel: + 44 1634 829386
[email protected]
management
bruce poorman
President & Publisher
[email protected]
laurence doyle
Executive VP & General Manager
[email protected]
marGe Gorsline
Operations Manager
[email protected]
DDNews
old river publicaTions, llc.
19035 Old Detroit Road, Suite 203
Rocky River, OH 44116
Tel: 440-331-6600
Fax: 440-331-7563
www.DDN-news.com